International Journal of Endocrinology

International Journal of Endocrinology / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 9132372 |

Fumiyoshi Yakou, Hirotsugu Suwanai, Takuya Ishikawa, Mariko Itou, Jumpei Shikuma, Takashi Miwa, Hiroyuki Sakai, Kohsuke Kanekura, Satoshi Narumi, Ryo Suzuki, Masato Odawara, "A Novel Homozygous Mutation of Thyroid Peroxidase Gene Abolishes a Disulfide Bond Leading to Congenital Hypothyroidism", International Journal of Endocrinology, vol. 2020, Article ID 9132372, 8 pages, 2020.

A Novel Homozygous Mutation of Thyroid Peroxidase Gene Abolishes a Disulfide Bond Leading to Congenital Hypothyroidism

Academic Editor: Diego Russo
Received03 Jul 2020
Revised12 Aug 2020
Accepted23 Aug 2020
Published30 Aug 2020


Congenital hypothyroidism (CH) is the most prevalent congenital endocrine disorder and causes mental retardation. A male Japanese patient with first cousin marriage parents was diagnosed as CH at 10 months. He was born before introduction of mass screening for CH. With continuous thyroid hormone replacement therapy, normal thyroid hormone status was maintained until adulthood. Genetic screening of next-generation sequencing was performed at the age of 52 years, and we identified a new homozygous thyroid peroxidase (TPO) gene mutation (GRCh38.p13, chromosome 2 at position 1493997, c.1964 G>T, p.Cys655Phe). TPO is an important enzyme to produce thyroid hormone. As demonstrated by a homology analysis of TPO proteins among different species, cysteine 655 residue is highly conserved, suggesting an important role in maintaining TPO function and structure. An in silico study with three-dimensional structure of the novel mutation was performed and suggested that the mutation abolished disulfide bond between cysteines at positions 598 and 655. An in vitro functional analysis using HEK293 cells revealed that TPO activity of the mutant was significantly impaired compared with that of the wild type. Furthermore, study of immunohistochemistry showed that localization of TPO in cells did not differ between the wild type and the mutant. In conclusion, this single disulfide bond loss mutation of a new TPO homozygous mutation, p.Cys655Phe, reduced TPO activity and caused congenital hypothyroidism without affecting subcellular localization of TPO proteins.

1. Introduction

Congenital hypothyroidism (CH) is the most prevalent congenital endocrine disorder and one of the preventable causes of mental retardation [1]. Prevalence of CH is approximately 1 in 2,000–4,000 newborns all over the world [2]. In Japan, mass screening for CH was introduced in 1979 and is usually performed in the neonatal period. Genetic screening of CH has been performed for research purpose and mainly eleven genes are related to CH such as TSHR, PAX8, NKX2-1, FOXE1, TG, TPO, SLC5A5, SLC26A4, IYD, DUOX2, and DUOXA2. Thyroid dysgenesis accounts for 80–85% cases, while 10 to 20% cases of CH are due to abnormalities in thyroid hormone synthesis [3]. Thyroid peroxidase (TPO) deficiency due to a biallelic TPO mutation is a representative genotype of CH [4]. Inheritance pattern of CH due to TPO mutation is autosomal recessive. Most patients with biallelic TPO mutations exhibit permanent CH.

TPO plays essential roles in thyroid hormone production. Oxidized iodide by TPO attaches to tyrosyl residues in thyroglobulin (Tg) to make monoiodotyrosine and diiodotyrosine, a process also catalyzed by TPO. Next, these iodotyrosyl residues couple in another TPO-mediated reaction to form an iodothyronine, triiodothyronine (T3), or thyroxine (T4) [5]. Therefore, individuals with low TPO activity may have insufficient thyroid hormone synthesis.

Here, we report a new homozygous TPO mutation (GRCh38.p13, chromosome 2 at position 1493997, c.1964 G>T, p.Cys655Phe) identified via genetic screening based on next-generation sequencing. To date, approximately 70 TPO mutations have been recorded in the Human Gene Mutation Database ( However, this is an unrecorded and novel mutation. Therefore, we performed conformational prediction and in vitro analyses of the novel TPO mutation in this case.

2. Materials and Methods

2.1. Patient

This study was approved by Tokyo Medical University, medical ethics committee (SH2932). Written informed consents were obtained from the proband and his elder brother. A male patient, the fourth child of healthy Japanese consanguineous parents, was born at term after an uneventful pregnancy and delivery. He was born in 1979, before the introduction of mass screening for CH. His family reported that the patient presented persistent drowsiness, could not drink breast milk, and was hospitalized soon after birth. Although he was treated with nutrition therapy, height and weight gains were delayed. He was diagnosed as CH at the age of 10 months based on the blood test, and thyroid hormone replacement therapy was initiated. His thyroid hormone status remained normal since then until now. There were no problems in his growth process, but he has a mild intelligence deficit. His age at the last visit was 52 years. He was 162 cm tall and weighed 58 kg. He has been our outpatient from the age of 37 years and has received thyroid hormone replacement therapy. At present, we continue administering him with levothyroxine at 150 μg/day. In palpation, his thyroid gland was soft, mobile, and symmetric. Recently, his hormone levels associated with thyroid were within the normal range at the last visit: serum TSH 1.04 μU/mL (reference 0.46–3.50) and free T4 1.50 ng/dL (reference 0.90–1.80). Serum Tg values during the visit term varied between 59.0 and 546.0 ng/ml (reference <32.7) in a few measurements. Serum levels of anti-Tg antibody and anti-TPO antibody were in normal range.

2.2. Detection and In Silico Analysis of TPO Mutation

Peripheral venous blood samples were obtained from the proband and his elder brother. Genomic DNA was extracted from peripheral blood leucocytes using the Gentra Puregene Blood Kit (Qiagen, Germany) according to the manufacturer’s protocol. The CH capture panel contained 11 known CH-related genes, 3 of which (PAX8, NKX2-1, and FOXE1) are involved in thyroid dysplasia [4]. TSHR is a hormone receptor involved in TSH signaling abnormalities. The remaining seven genes (TG, TPO, SLC5A5, SLC26A4, IYD, DUOX2, and DUOXA2) are involved in thyroid dyshormonogenesis [6].

For gene analysis, next-generation sequencer MiSeq (Illumina Inc, San Diego, CA, USA) was used according to the SureSelect protocol (Agilent Technologies, Santa Clara, CA, USA), as described previously [7]. Using the Illumina processing pipeline, base calling, read filtering, and demultiplexing were performed. BWA 0.7.17 was used for alignment against the human reference genome (NCBI build 37; hg19) [8]. Local realignment, quality score recalibration, and variant calling were performed using GATK 3.8 with default settings [9]. ANNOVAR was used for the annotation of the detected variants [10]. ClustalW (version 2.1) was utilized to perform multiple sequence alignment of TPO family proteins from different species [11].

The detected mutation was confirmed using standard polymerase chain reaction- (PCR-) based Sanger sequencing, as described previously [12]. We referred to mutation frequencies in variant databases, including the Genome Aggregation Database (, 1,000 Genomes Project (, Human Genetic Variation Database (, and ToMMo 4.7KJPN ( Descriptions of the mutations were based on Homo sapiens TPO (National Center for Biotechnology Information (NCBI), reference sequence: NM_000547.5).

In silico studies were performed with the wild type (WT) and mutant TPO variants using PyMOL 0.9 to evaluate the three-dimensional (3D) structure of p.Cys655Phe TPO [13]. For the conformational prediction of TPO, human myeloperoxidase (MPO) 3D structure was used as a template. MPO is known as the closest homolog to TPO and shares 47% sequence identity with the MPO-like domain of TPO [14, 15]. The X-ray crystal structure of human MPO has been previously determined (PDB accession code 3F9P) [16].

2.3. Cell Culture and Functional Analyses

HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium that was supplemented with 50 U/mL penicillin, 50 μg/mL streptomycin, and 10% fetal bovine serum. An expression vector encoding C-terminal hemagglutinin-tagged human TPO (TPO-HA) was created by inserting the TPO cDNA sequence into pEGFP-N1 (Clontech laboratories, Palo Alto, CA) as previously described [17]. After inserting the TPO cDNA sequence into pB513B-1 (System Biosciences, Palo Alto, CA, USA), an expression vector for stable TPO expression (WT) was created. A novel TPO mutation (p.Cys655Phe) expression vector was created by site-directed mutagenesis. The stable human embryonic kidney 293 (HEK293) cell lines expressing each TPO protein (WT, p.Cys655Phe) was established using the PiggyBac system according to the manufacturer’s protocol.

Cell transfection was performed using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, #L3000008). The cells were seeded into 12-well tissue culture plates at a density of 0.1 × 106 cells/well to reach approximately 70%–90% confluence for transfection. Transfection reagent and 1 μg DNA (composed of 750 ng p.Cys655Phe expression vector and 250 ng transposase) were added to 100 μL Opti-MEM medium and placed at room temperature for 5 minutes. Mixtures were added to the seeded cells and were cultured in an incubator at 37°C, 5% CO2 for 3 hours. After incubation, the cells were replaced with the conventional medium and selected by puromycin and cultured sequentially for 48 hours. Transfected cells were continuously cultured, as described above, and stable HEK293 cell lines expressing each TPO protein (WT, p.Cys655Phe) were established.

For TPO activity measurement, we prepared 90% confluent stable cells expressing each TPO protein (WT, p.Cys655Phe) in 12-well dishes. Cells were trypsinized, washed with phosphate buffered saline, and resuspended in 1X Earle’s balanced salt solution (Sigma Aldrich, St. Louis, MO, USA) containing 100 μM Amplex Red reagent (Thermo Fisher Scientific) and 2 mM H2O2, as previously described [18]. After transferring to a 96-well plate, the mixtures were incubated at 37°C for 1 hour and stirred frequently. Fluorescent emission was measured using EnSpire™ Alpha (Molecular Devices, PerkinElmer, Inc, Waltham, MA, USA) to quantify TPO activity of the cells. TPO activity of the new mutant is expressed as percentage (mean ± standard error of the mean (SEM)) of the WT activity. The background activity, which was measured using nontransfected cells (control), was set to 0%. The above experiment is representative of procedures performed independently three times and obtained similar results. values <0.05 obtained using Student’s t-test were considered significant.

2.4. Western Blot Analysis

Stable cells were grown in a 100 mm plate to approximately 90% confluency, washed twice with PBS, and lysed using the RIPA Lysis Buffer System (Santa Cruz, Dallas, TX, USA, #sc-24948) protein extraction method. Western blotting was performed using anti-TPO rabbit monoclonal antibodies (Abcam, Cambridge, MA, USA; ab109383) as the primary antibody and KPL peroxidase-labeled antibodies to rabbit IgG (H+L) (SeraCare, Milford, USA; 5220-0336) as the secondary antibody. Furthermore, we used mouse monoclonal anti-beta-actin (Abcam, Cambridge, MA, USA; ab8226) as the primary antibody of the loading control and rabbit anti-mouse IgG H&L (Abcam, Cambridge, MA, USA; ab6728) as the secondary antibody. Each band was analyzed using image processing software ImageJ (, and the expression levels were examined. Reverse transcription of RNA and the real-time PCR were performed according to manufacturer’s instructions, using KAPA SYBR FAST quantitative PCR Master Mix Kit (KAPA BIOSYSTEMS, Cape Town, South Africa; KK4601) and quantitative PCR primer pairs for TPO (NCBI Reference Sequence: BC095448; forward primer sequence: 5′-AACAACAGAGACCACCCCAGAT-3′, reverse primer sequence: 5′-TGACTGAAGCCGTCCTCATAGAC-3′) or housekeeping gene hprt1 (NCBI Reference Sequence: NM_000194; forward primer sequence: 5′-CATTATGCTGAGGATTTGGAAAGG-3′, reverse primer sequence: 5′-CTTGAGCACACAGAGGGCTACA-3′). TPO quantitative PCR were shown in arbitrary units of TPO mRNA/hprt1 as the mean ± standard error of the mean.

2.5. Immunohistochemistry

HEK293 cells overexpressing wild type or mutant TPO were seeded on a chambered coverglass and then transfected with pDsRed2-ER Vector (Clontech laboratories, Palo Alto, CA, 632409). Twenty-four hours after transfection, the cells were fixed with 10% formalin-phosphate buffer solution (PBS) for 15 minutes at room temperature. After washing three times with PBS, the cells were treated with or without 0.5% Triton-X100 for permeabilization, blocked with BlockingOne (Nacalai tesque, Kyoto, Japan, 03953-66), and incubated with anti-TPO antibody (Abcam, Cambridge, MA, USA; ab109383) for 2 hours at room temperature. After washing four times with PBS, the cells were incubated with Alexa-Fluor488 labeled Goat anti-Rabbit IgG (H+L) secondary antibody (Thermo Scientific, #A32731) for 1 hour at room temperature in a dark room. After washing four times with PBS, the cells were mounted with ProLong Gold with DAPI solution (Thermo Scientific, #3693).

3. Results

3.1. Mutation Analysis of the TPO Gene

Genetic screening of next-generation sequencing for the proband was performed, and a new homozygous TPO gene mutation (GRCh38.p13, chromosome 2 at position 1493997, c.1964 G> T, p.Cys655Phe) was identified. He did not have any mutations in the remaining genes that were analyzed. A homozygous novel TPO mutation was confirmed via Sanger sequencing (Figure 1(a) red arrow; Figure 1(c) II-4). His sibling (Figure 1(b); Figure 1(c), II-1) had the same mutation in the state of heterozygous confirmed by Sanger sequencing. His parents were first cousins (Figure 1(c), I-1 and I-2) and probably carriers of heterozygous TPO mutation. The patient’s mother had already died, and his father was too old to visit. Therefore, blood samples of parents could not be collected.

Thyroid ultrasonography showed mildly enlarged thyroid (estimated volume, 22.9 mL; Figure 1(d)), uneven internal echo imaging, and increased internal blood flow (Figure 1(e)). His elder brother (Figure 1(c), II-1) has no goiter and has normal thyroid hormone levels, with no conspicuous abnormalities observed in growth, intelligence, and adolescent development. His elder sister (Figure 1(c), II-2) and second brother (Figure 1(c), II-3) died shortly after birth. Detailed records were not available. According to family information, autopsy of both children revealed enlarged thyroid glands. The family had no history of thyroid cancer.

Homology analyses of protein sequences across species were performed around Cys655 of human TPO proteins using ClustalW 2.1 software. The Cys655 residue substituted with the mutant was highly conserved among mammalian species (Figure 2).

3.2. Conformational Prediction

As demonstrated by mutation detection, the cysteine 655 residue is within a highly conserved region of TPO, suggesting its important role in TPO function and structure. Cysteines can joint between side chains via disulfide bonds as part of the secondary and tertiary structures of proteins. A comparison of the predicted tertiary structure of the WT and mutant protein revealed that the novel TPO mutation p.Cys655Phe abolishes disulfide bonds between cysteines at positions 598 and 655 (Figures 3(a)3(c)).

3.3. Functional Analysis

We performed in vitro expression experiments to ascertain the pathogenicity of a novel mutation (p.Cys655Phe). HEK293 cell lines that stably express each TPO protein (WT or mutant) were established using PiggyBac system. Western blots were performed in triplicate between wild-type, mutant, and control cells (Figure 4(a)). As a result of comparing expression levels with ImageJ, mutant TPO expression normalized against beta-actin was significantly reduced as compared with the wild type. When the wild-type TPO expression level was set to 1, the mutant TPO expression level was 0.274 (Figure 4(b), ). In addition, there was no significant difference between wild type and mutant () of RNA expression using real-time PCR (Figure 4(c)). Peroxidase activity in those cell lines was measured using the Amplex Red reaction. The assay of Amplex Red reaction showed that the p.Cys655Phe-TPO had strikingly low peroxidase activity, which was 16.4 ± 8.6% () of WT-TPO (Figure 4(d)).

3.4. Immunohistochemistry of TPO

Immunofluorescence studies were performed to determine the localization of TPO proteins. Immunocytochemical analyses were performed with each cell line expressing wild-type TPO or mutant TPO under both permeabilized and nonpermeabilized conditions (Figures 5(a) and 5(b)). The results indicate that both wild-type TPO and mutant TPO localize to the cell membrane and endoplasmic reticulum.

4. Discussion

Using next-generation sequencing, we revealed a novel homozygous TPO mutation (c.1964 G>T, p.Cys655Phe) in the patient with CH. To date, more than 70 TPO mutations have been reported, but only some of them have been assessed in vitro for enzyme activity [1722]. We demonstrated through in vitro experiments that the TPO activity of the new mutant is significantly lower than that of the WT. Using a molecular graphic tool, we created a three-dimensional image of the molecular structure of this new mutation TPO and confirmed that disulfide bonds disappeared with amino acid substitution.

Proteins inside the endoplasmic reticulum fold correctly by forming disulfide bonds. It has been previously discussed that substitution of cysteine residue disrupted disulfide bridges and induced CH [23]. It is unclear whether TPO mutations prevent intracellular translocation to the plasma membrane surface in thyroid follicular cells. In previous study, a TPO mutation of p.Cys825Arg reported by Zhao et al. has substitutional malfunction of a disulfide-forming cysteine residue in TPO protein [24]. Our experiments revealed that mutant TPO protein (p.Cys655Phe) was abundant not only in the cell membrane but also in the cytoplasm, especially in the endoplasmic reticulum even under nonpermeabilized condition.

5. Conclusion

In conclusion, a new TPO homozygous mutation (p.Cys655Phe) was identified in a Japanese family. This single disulfide bond loss mutation reduced TPO activity and caused congenital hypothyroidism without affecting subcellular localization of TPO proteins.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

F.Y. and H.S. designed the project. S.N. conducted the sequencing analyses. F.Y. performed in vitro experiments. K.K. performed immunocytochemical analysis. H.S. and F.Y. clinically characterized the patient and collected biological samples. S.N. conducted the conformational prediction. F.Y. wrote the manuscript. T.I., M.I., J.S., T.M., R.S., S.N., M.O., and H.S. edited the manuscript.


This study was partly supported by the Grant-in-Aid for Challenging Exploratory Research (19K22607) for S.N. and the follow-up research grant of Tokyo Medical University for H.S. The authors thank Ms. Yoshiko Togawa and Mr. Tomoaki Miyamoto for technical assistance.


  1. R. S. Amparo, J. C. G. María, A. M. María et al., “Diagnosis and follow-up of patients with congenital hypothyroidism detected by neonatal screening,” Anales de Pediatria, vol. 90, no. 4, pp. 250.e1–250.e8, 2019. View at: Google Scholar
  2. M. V. Rastogi and S. H. LaFranchi, “Congenital hypothyroidism,” Orphanet Journal of Rare Diseases, vol. 5, p. 17, 2010. View at: Publisher Site | Google Scholar
  3. C. C. Lee, F. Harun, M. Y. Jalaludin et al., “Functional analyses of C.2268dup in thyroid peroxidase gene associated with goitrous congenital hypothyroidism,” BioMed Research International, vol. 2014, Article ID 370538, 11 pages, 2014. View at: Publisher Site | Google Scholar
  4. C. Fu, B. Xie, S. Zhang et al., “Mutation screening of the TPO gene in a cohort of 192 Chinese patients with congenital hypothyroidism,” BMJ Open, vol. 6, no. 5, Article ID e010719, 2016. View at: Publisher Site | Google Scholar
  5. J. T. Dunn and A. D. Dunn, “Update on intrathyroidal iodine metabolism,” Thyroid, vol. 11, no. 5, pp. 407–414, 2001. View at: Publisher Site | Google Scholar
  6. H. Cangul, Z. Aycan, A. Olivera-Nappa et al., “Thyroid dyshormonogenesis is mainly caused by TPO mutations in consanguineous community,” Clinical Endocrinology, vol. 79, no. 2, pp. 275–281, 2013. View at: Publisher Site | Google Scholar
  7. A. Yoshizawa-Ogasawara, K. Abe, S. Ogikubo et al., “Transient congenital hypothyroidism caused by compound heterozygous mutations affecting the NADPH-oxidase domain of DUOX2,” Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 3, pp. 363–371, 2016. View at: Publisher Site | Google Scholar
  8. H. Li and R. Durbin, “Fast and accurate short read alignment with burrows-wheeler transform,” Bioinformatics, vol. 25, no. 14, pp. 1754–1760, 2009. View at: Publisher Site | Google Scholar
  9. A. McKenna, M. Hanna, E. Banks et al., “The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data,” Genome Research, vol. 20, no. 9, pp. 1297–1303, 2010. View at: Publisher Site | Google Scholar
  10. K. Wang, M. Li, and H. Hakonarson, “ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data,” Nucleic Acids Research, vol. 38, no. 16, p. e164, 2010. View at: Publisher Site | Google Scholar
  11. M. A. Larkin, G. Blackshields, N. P. Brown et al., “Clustal W and clustal X version 2.0,” Bioinformatics, vol. 23, no. 21, pp. 2947-2948, 2007. View at: Publisher Site | Google Scholar
  12. S. Narumi, K. Muroya, Y. Asakura, M. Aachi, and T. Hasegawa, “Molecular basis of thyroid dyshormonogenesis: genetic screening in population-based Japanese patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 11, pp. E1838–E1842, 2011. View at: Publisher Site | Google Scholar
  13. G. Janson, C. Zhang, M. G. Prado, and A. Paiardini, “PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL,” Bioinformatics (Oxford, England), vol. 33, no. 3, pp. 444–446, 2017. View at: Google Scholar
  14. M. N. Begum, M. T. Islam, H. R. Hossain et al., “Mutation spectrum in TPO gene of Bangladeshi patients with thyroid dyshormonogenesis and analysis of the effects of different mutations on the structural features and functions of TPO protein through in silico approach,” BioMed Research International, vol. 2019, Article ID 9218903, 18 pages, 2019. View at: Publisher Site | Google Scholar
  15. S. N. Le, B. T. Porebski, J. McCoey et al., “Modelling of thyroid peroxidase reveals insights into its enzyme function and autoantigenicity,” PLoS One, vol. 10, no. 12, Article ID e0142615, 2015. View at: Publisher Site | Google Scholar
  16. T. J. Fiedler, C. A. Davey, and R. E. Fenna, “X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 Å resolution,” Journal of Biological Chemistry, vol. 275, no. 16, pp. 11964–11971, 2000. View at: Publisher Site | Google Scholar
  17. K. Umeki, T. Kotani, J. Kawano et al., “Two novel missense mutations in the thyroid peroxidase gene, R665W and G771R, result in a localization defect and cause congenital hypothyroidism,” European Journal of Endocrinology, vol. 146, no. 4, pp. 491–498, 2002. View at: Publisher Site | Google Scholar
  18. S. Narumi, L. A. Fox, K. Fukudome et al., “Mild thyroid peroxidase deficiency caused by TPO mutations with residual activity: correlation between clinical phenotypes and enzymatic activity,” Endocrine Journal, vol. 64, no. 11, pp. 1087–1097, 2017. View at: Publisher Site | Google Scholar
  19. H. Bikker, F. Baas, and J. J. M. De Vijlder, “Molecular analysis of mutated thyroid peroxidase detected in patients with total iodide organification defects,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 2, pp. 649–653, 1997. View at: Publisher Site | Google Scholar
  20. T. Kotani, K. Umeki, I. Yamamoto, H. Maesaka, K. Tachibana, and S. Ohtaki, “A novel mutation in the human thyroid peroxidase gene resulting in a total iodide organification defect,” Journal of Endocrinology, vol. 160, no. 2, pp. 267–273, 1999. View at: Publisher Site | Google Scholar
  21. T. Kotani, K. Umeki, J.-i. Kawano et al., “A novel missense mutation in the thyroid peroxidase gene, R175Q, resulting in insufficient cell surface enzyme in two siblings,” Clinical Pediatric Endocrinology, vol. 13, no. 1, pp. 37–46, 2004. View at: Publisher Site | Google Scholar
  22. T. Kotani, K. Umeki, J.-I. Kawano et al., “Partial iodide organification defect caused by a novel mutation of the thyroid peroxidase gene in three siblings,” Clinical Endocrinology, vol. 59, no. 2, pp. 198–206, 2003. View at: Publisher Site | Google Scholar
  23. K. Börgel, J. Pohlenz, W. Holzgreve, and J. H. Bramswig, “Intrauterine therapy of goitrous hypothyroidism in a boy with a new compound heterozygous mutation (Y453D and C800R) in the thyroid peroxidase gene. A long-term follow-up,” American Journal of Obstetrics and Gynecology, vol. 193, no. 3, pp. 857-858, 2005. View at: Publisher Site | Google Scholar
  24. D. Zhao, Y. Li, Z. Shan et al., “Functional analysis of thyroid peroxidase gene mutations resulting in congenital hypothyroidism,” Clinical Endocrinology, 2020. View at: Publisher Site | Google Scholar

Copyright © 2020 Fumiyoshi Yakou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.